Johnson & Johnson's earnings report is highly anticipated, with Wall Street estimating revenue at $22.86 billion and normalized EPS at $2.68. The stock remains strong, up nearly 8% year-to-date, despite a 1.8% sell-off in the healthcare sector recently. Key factors impacting the stock today include potential issues surrounding the loss of exclusivity for STELARA and the growth outlook in the MedTech sector. These elements could be pivotal for stock performance in the immediate future.
Johnson & Johnson is experiencing strong stock performance with an 8% year-to-date increase, backed by a 3.3% dividend yield, amid broader healthcare sector selling.
Wall Street anticipates significant earnings from Johnson & Johnson, expecting revenue to reach $22.86 billion and a normalized EPS of $2.68 in the upcoming report.
Collection
[
|
...
]